​

Funding Round

Series C - AgomAb Therapeutics

Series C - AgomAb Therapeutics

Investment Firm

Overview

AgomAb Therapeutics is a Company is developing growth factor-mimetic agonistic monoclonal antibodies to regenerate damaged tissues.

Announced Date

Oct 11, 2023

Funding Type

Series C

Highlights

Location

Europe

Social

Investor Lead

Fidelity

Fidelity

Fidelity is a convertible_note and debt and early_stage_venture and late_stage_venture and post_ipo and private_equity and secondary_market and seed firm.

Participant Investors

10

Investor Name
Participant InvestorPfizer
Participant InvestorEQT Life Sciences
Participant InvestorAndera Partners
Participant InvestorCanaan Partners
Participant InvestorFidelity

Round Details and Background

AgomAb Therapeutics raised $100817696 on 2023-10-11 in Series C

AgomAb Therapeutics is a Company is developing growth factor-mimetic agonistic monoclonal antibodies to regenerate damaged tissues.

Company Funding History

4

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Mar 10, 2021
Series B - AgomAb Therapeutics
8-74.0M
Apr 03, 2019
Series A - AgomAb Therapeutics
5-23.6M
Jul 13, 2022
Series B - AgomAb Therapeutics
3-38.5M
Oct 11, 2023
Series C - AgomAb Therapeutics
12-100.8M

Recent Activity

There is no recent news or activity for this profile.